SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

CAPS Rating: 5 out of 5

A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.

Recs

0
Player Avatar markmark69 (< 20) Submitted: 2/26/2013 12:02:18 PM : Outperform Start Price: $4.64 SCLN Score: +39.78

No debt, huge cashflow. One of the few US based companies with market penetration in China.

Featured Broker Partners


Advertisement